Experienced in Mantle Cell Lymphoma (MCL)

Judith Dierlamm

Hamburg, HH, DE 
Experienced in Mantle Cell Lymphoma (MCL)
Hamburg, HH, DE 
OverviewLocationsClinical Research

Overview

Judith Dierlamm practices in Hamburg, Germany. Ms. Dierlamm is rated as an Experienced expert by MediFind in the treatment of Mantle Cell Lymphoma (MCL). Her top areas of expertise are B-Cell Lymphoma, Burkitt Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 40 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles and participated in 1 clinical trial in the study of Mantle Cell Lymphoma (MCL).

Gender
Female

Locations

Hamburg, HH, Germany
Other Locations
Eppendorf, HH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3

40 Total Publications

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.
Journal: The Lancet. Oncology
Published: November 08, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Dierlamm's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile